Business
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform
Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company, today announced that its wholly owned subsidiary, Velocity Bioworks, has entered into an exclusive commercial development and license agreement with LarmorBio, Inc. ("LarmorBio") for LarmorBio's BioScan-NMR™ platform, a next-generation nuclear magnetic resonance (NMR) system. Under the agreement, Velocity Bioworks will host the first commercial deployment of the BioScan-NMR platfor
About this update from Valion Bio, Inc.
[{"type":"text","content":"First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Generation NMR-Based Diagnostics","length":179,"tagName":"p"},{"type":"text","content":"SAN ANTONIO, May 14, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company, today announced that its wholly owned subsidiary, Velocity Bioworks, has entered into an exclusive commercial development and license agreement with LarmorBio, Inc. ("LarmorBio") for LarmorBio's BioScan-NMR™ platform, a next-generation nuclear magnetic resonance (NMR) system. Under the agreement, Velocity Bioworks will host the first commercial deployment of the BioScan-NMR platform, with installation and commissioning at the Company's San Antonio facility targeted for July 2026.","length":660,"tagName":"p"},{"type":"image","alt":"VALION BIO, INC (PRNewsfoto/Valion Bio, Inc.)","displaySize":"","headline":null,"caption":"VALION BIO, INC (PRNewsfoto/Valion Bio, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/6a1c19825a3562d437f1cb371710ca86"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OFWQFJvnfWBH7yFC1odhhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNQ--/https://media.zenfs.com/en/prnewswire.com/6a1c19825a3562d437f1cb371710ca86","width":400,"height":400},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/VgvUJ.uCTODLXXC3bhg1bA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTY0MA--/https://media.zenfs.com/en/prnewswire.com/6a1c19825a3562d437f1cb371710ca86","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2972189/Valion_Logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Valion Bio secured the exclusive license and reference site arrangement at pre-institutional pricing, ahead of LarmorBio's pending Series A financing. The structure aligns the two companies as co-dependent strategic partners — rather than in a conventional vendor-customer relationship — with both parties commercially and operationally aligned on the validation, optimization, and scaled deployment of the BioScan-NMR platform.","length":432,"tagName":"p"},{"type":"text","content":""Securing exclusive commercial rights to...